These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30594925)

  • 1. Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment.
    Oeckl P; Halbgebauer S; Anderl-Straub S; Steinacker P; Huss AM; Neugebauer H; von Arnim CAF; Diehl-Schmid J; Grimmer T; Kornhuber J; Lewczuk P; Danek A; ; Ludolph AC; Otto M
    J Alzheimers Dis; 2019; 67(2):481-488. PubMed ID: 30594925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
    Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
    J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
    Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
    J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of behavioral and psychological symptoms on caregiver burden in frontotemporal dementia, Lewy body dementia, and Alzheimer's disease: clinical experience in China.
    Liu S; Jin Y; Shi Z; Huo YR; Guan Y; Liu M; Liu S; Ji Y
    Aging Ment Health; 2017 Jun; 21(6):651-657. PubMed ID: 26882509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential diagnosis between patients with probable Alzheimer's disease, Parkinson's disease dementia, or dementia with Lewy bodies and frontotemporal dementia, behavioral variant, using quantitative electroencephalographic features.
    Garn H; Coronel C; Waser M; Caravias G; Ransmayr G
    J Neural Transm (Vienna); 2017 May; 124(5):569-581. PubMed ID: 28243755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum neurofilament light chain in behavioral variant frontotemporal dementia.
    Steinacker P; Anderl-Straub S; Diehl-Schmid J; Semler E; Uttner I; von Arnim CAF; Barthel H; Danek A; Fassbender K; Fliessbach K; Foerstl H; Grimmer T; Huppertz HJ; Jahn H; Kassubek J; Kornhuber J; Landwehrmeyer B; Lauer M; Maler JM; Mayer B; Oeckl P; Prudlo J; Schneider A; Volk AE; Wiltfang J; Schroeter ML; Ludolph AC; Otto M;
    Neurology; 2018 Oct; 91(15):e1390-e1401. PubMed ID: 30209235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S; Vermeiren Y; Fransen E; Van Dam D; Aerts T; Gerritsen MJ; Spikman JM; van Laar T; De Deyn PP
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
    Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up.
    Bonanni L; Thomas A; Tiraboschi P; Perfetti B; Varanese S; Onofrj M
    Brain; 2008 Mar; 131(Pt 3):690-705. PubMed ID: 18202105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers.
    Dodich A; Cerami C; Cappa SF; Marcone A; Golzi V; Zamboni M; Giusti MC; Iannaccone S
    J Alzheimers Dis; 2018; 61(2):761-772. PubMed ID: 29254091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.
    Andersson M; Zetterberg H; Minthon L; Blennow K; Londos E
    Int J Geriatr Psychiatry; 2011 Jan; 26(1):100-5. PubMed ID: 21157855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.
    Aarsland D; Litvan I; Salmon D; Galasko D; Wentzel-Larsen T; Larsen JP
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1215-20. PubMed ID: 12933921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.